Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCP 424174 is an inhibitor of IL-1β post-translational processing (IC50 = 210 nM). Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
Sold for research purposes under agreement from Pfizer Inc.
分子量 | 452.99 |
公式 | C22H29ClN2O4S |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 210825-31-3 |
PubChem ID | 9911728 |
InChI Key | YRSBLSHMKVQWHP-UHFFFAOYSA-N |
Smiles | O=S(C1=CC(C(O)(C)C)=CC=C1)(NC(NC2=C(C(C)C)C=C(Cl)C=C2C(C)C)=O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Perregaux et al (2001) Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J.Pharmacol.Exp.Ther. 299 187 PMID: 11561079
Baldwin et al (2016) Inhibiting the inflammasome: a chemical perspective. J.Med.Chem. 59 1691 PMID: 26422006
关键词: CP 424174, CP 424174 supplier, CP424174, Inhibitor, IL-1, beta, post-translational, processing, β, NLRP3, inflammasomes, in, vivo, orally, bioavailable, Cytokines, Inflammasomes, 6107, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CP 424174 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.